

490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527

Supplementary Materials for

Impaired biogenesis of basic proteins impacts multiple hallmarks of the aging brain

Domenico Di Fraia^{1,*}, Antonio Marino^{1,*}, Jae Ho Lee^{2,*}, Erika Kelmer Sacramento¹, Mario Baumgart¹, Sara Bagnoli³, Pedro Tomaz da Silva^{4,5}, Amit Kumar Sahu¹, Giacomo Siano³, Max Tiessen¹, Eva Terzibasi-Tozzini³, Julien Gagneur^{4,6,7}, Judith Frydman^{2,#}, Alessandro Cellerino^{1,3,#}, and Alessandro Ori^{1,#,§}

Corresponding author: jfrydman@stanford.edu, alessandro.cellerino@leibniz-fli.de or alessandro.ori@leibniz-fli.de

The PDF file includes:

Materials and Methods
Supplementary Text
Figures S1 to S9
References

528 **Materials and methods**

529

530 **Animal management practices**

531 All experiments were performed in accordance with relevant guidelines and regulations. Fish were bred
532 and kept in FLI's fish facility according to §11 of the German Animal Welfare Act under license number
533 J-003798. The animal experiment protocols were approved by the local authority in the State of
534 Thuringia (Veterinaer- und Lebensmittelueberwachungsamt; proteasome impairment: reference
535 number 22-2684-04-FLI-19-010). Sacrifice and organ harvesting of non-experimental animals were
536 performed according to §4(3) of the German Animal Welfare Act.

537

538 ***In vivo* proteasome impairment**

539 Adult animals (12–14 wph) were subjected to pharmacological intervention via intraperitoneal
540 injections (IP) during a 4-weeks period of treatment. On each of the sixth day ($t = 0$, $t = 6$ d, $t = 12$ d, t
541 $= 18$ d, $t = 24$ d), fish were anesthetized with 200 mg/l buffered MS-222 (PharmaQ) and gently
542 manipulated to deliver IP of Bortezomib at 500 μ M or vehicle (1% DMSO in a physiological salt
543 solution) at a dosage of 10 μ l/g body weight. Animals from the same hatch were randomly allocated to
544 the experimental groups. Both male and female fish were included in each experimental group.
545 Individual brains from the fish were collected on the last day of treatment and snap-frozen in liquid
546 nitrogen.

547

548 **Proteasome activity assay**

549 CT-L (chymotrypsin-like) proteasome activity was assayed with the hydrolysis of a specific fluorogenic
550 substrate, Suc-LLVY-AMC (UBPBio, Catalog Number G1100). On the day of the experiment, brains
551 were lysed in buffer (50 mM HEPES, pH 7.5 (Sigma Aldrich, H3375); 5 mM EDTA (Carl Roth,
552 8043.2); 150 mM NaCl (Carl Roth, 3957.1); 1 % (v/v) Triton X-100 (Carl Roth, 3051.3); 2 mM ATP
553 (Sigma Aldrich, A2383) prepared with Milli-Q water) to a final estimated protein concentration of \sim 4
554 mg/mL and homogenized by sonication (Bioruptor Plus) for 10 cycles (30 sec ON/60 sec OFF) at high
555 setting, at 4°C. Lysates corresponding to 10 μ g protein were incubated in 50 mM Tris-HCl, pH 7.4, 5
556 mM MgCl₂, 1 mM ATP, 1 mM DTT, 10% glycerol, and 10 μ M proteasome substrate for 1 h at 37 °C.
557 Specific proteasome activity was determined as the difference between the total activity of protein
558 extracts and the remaining activity in the presence of 20 μ M MG132 (Enzo Life Sciences, BML-PI102-
559 0005). Fluorescence was measured by multiple reads for 60 min at 37°C by TECAN Kinetic Analysis
560 (excitation 380 nm, emission 460 nm, read interval 5 min) on a Safire II microplate reader (TECAN).

561

562 **Sample preparation for total proteome and analysis of PTMs**

563 Snap-frozen brains were thawed and transferred into Precellys® lysing kit tubes (Keramik-kit
564 1.4/2.8 mm, 2 ml (CKM)) containing 150 μ l of PBS supplemented with cOmplete™, Mini, EDTA-free
565 Protease Inhibitor (Roche,11836170001) and with PhosSTOP™ Phosphatase Inhibitor (Roche,
566 4906837001). Based on estimated protein content (5% of fresh tissue weight), three to six brains were
567 pooled to obtain \sim 1.5 mg of protein extract as starting material for each biological replicate. Tissues
568 were homogenized twice at 6000 rpm for 30 s using Precellys® 24 Dual (Bertin Instruments, Montigny-
569 le-Bretonneux, France), and the homogenates were transferred to new 2 ml Eppendorf tubes. Proteins
570 were quantified using Pierce™ BCA Protein Assay Kit (Thermo Scientific, 23225), and 1.25 mg was
571 processed for further analysis. Volumes were adjusted using PBS and one-fourth of the volume
572 equivalent of the 4 \times lysis (8% SDS, 100 mM HEPES, pH8) buffer was added. Samples were sonicated
573 twice in a Bioruptor Plus for 10 cycles with 1 min ON and 30 s OFF with high intensity at 20 °C. The
574 lysates were centrifuged at 18,407 xg for 1 min and transferred to new 1.5 ml Eppendorf tubes.

575 Subsequently, samples were reduced using 10 mM DTT (Carl Roth, 6908) for 15 min at 45 °C and
576 alkylated using freshly made 200 mM iodoacetamide (IAA) (Sigma-Aldrich, I1149) for 30 min at room
577 temperature in the dark. An aliquot of each lysate was used for estimating the precise protein quantity
578 using BCA (Thermo Scientific, 23225). Subsequently, proteins were precipitated using cold acetone,
579 as described in (64), and resuspended in 500 µl of digestion buffer (3 M urea, 100 mM HEPES pH 8.0).
580 Aliquots corresponding to 20, 200, and 1000 µg protein were taken for proteome, phosphopeptides, and
581 ubiquitylated/acetylated peptides enrichment, respectively, and digested using LysC 1:100
582 enzyme:proteins ratio for 4 hours (Wako sequencing grade, 125-05061) and trypsin 1:100
583 enzyme:proteins ratio for 16 hours (Promega sequencing grade, V5111). The digested proteins were
584 then acidified with 10% (v/v) trifluoroacetic acid and desalted using Waters Oasis® HLB µElution Plate
585 30 µm (2, 10, and 30 mg, depending on the amount of starting material) following manufacturer
586 instructions. The eluates were dried down using a vacuum concentrator and reconstituted in MS buffer
587 A (5% (v/v) acetonitrile, 0.1% (v/v) formic acid). For PTM enrichment, peptides were further processed
588 as described below. For Data Independent Acquisition (DIA) based analysis of total proteome, samples
589 were transferred to MS vials, diluted to a concentration of 1 µg/µL, and spiked with iRT kit peptides
590 (Biognosys, Ki-3002-2) prior to analysis by LC-MS/MS.

591

592 **Sequential enrichment of ubiquitylated and acetylated peptides**

593 Ubiquitylated and acetylated peptides were sequentially enriched starting from ~1000 µg of dried
594 peptides per replicate. For the enrichment of ubiquitylated peptides, the PTMScan® HS
595 Ubiquitin/SUMO Remnant Motif (K-ε-GG) kit (Cell Signaling Technology, 59322) was used following
596 manufacturer instructions. The K-ε-GG modified enriched fraction was desalted and concentrated as
597 described above, dissolved in MS buffer A, and spiked with iRT kit peptides prior to LC-MS/MS
598 analysis. The flowthrough fractions from the K-ε-GG enrichment were acidified with 10% (v/v)
599 trifluoroacetic acid and desalted using Oasis® HLB µElution Plate 30 µm (30 mg) following
600 manufacturer instructions. Acetylated peptides were enriched as described by (65). Briefly, dried
601 peptides were dissolved in 1000 µl of IP buffer (50 mM MOPS pH 7.3, 10 mM KPO₄ pH 7.5, 50 mM
602 NaCl, 2.5 mM Octyl β-D-glucopyranoside) to reach a peptide concentration of 1 µg/µL, followed by
603 sonication in a Bioruptor Plus (5 cycles with 1 min ON and 30 s OFF with high intensity at 20 °C).
604 Agarose beads coupled to an antibody against acetyl-lysine (ImmuneChem Pharmaceuticals Inc.,
605 ICP0388-5MG) were washed three times with washing buffer (20 mM MOPS pH 7.4, 10 mM KPO₄
606 pH 7.5, 50 mM NaCl) before incubation with each peptide sample for 1.5 h on a rotating well at 750 rpm
607 (STARLAB Tube roller Mixer RM Multi-1). Samples were transferred into Clearspin filter microtubes
608 (0.22 µm) (Dominique Dutscher SAS, Brumath, 007857ACL) and centrifuged at 4 °C for 1 min at 2000
609 xg. Beads were washed first with IP buffer (three times), then with washing buffer (three times), and
610 finally with 5 mM ammonium bicarbonate (three times). Thereupon, the enriched peptides were eluted
611 first in basic condition using 50 mM aqueous NH₃, then using 0.1% (v/v) trifluoroacetic acid in 10%
612 (v/v) 2-propanol and finally with 0.1% (v/v) trifluoroacetic acid. Elutions were dried down and
613 reconstituted in MS buffer A (5% (v/v) acetonitrile, 0.1% (v/v) formic acid), acidified with 10% (v/v)
614 trifluoroacetic acid, and then desalted with Oasis® HLB µElution Plate 30 µm. Desalted peptides were
615 finally dissolved in MS buffer A, spiked with iRT kit peptides and analyzed by LC-MS/MS.

616

617

618

619

620 **Enrichment of phosphorylated peptides**

621 Lysates (corresponding to ~200 µg of protein extract) were acetone precipitated, digested into peptides,
622 and desalted, as described in “Sample preparation for total proteome and analysis of PTMs”. The last
623 desalting step was performed using 50 µl of 80% ACN and 0.1% TFA buffer solution. Before
624 phosphopeptide enrichment, samples were filled up to 210 µl using 80% ACN and 0.1% TFA buffer
625 solution. Phosphorylated peptides were enriched using Fe(III)-NTA cartridges (Agilent Technologies,
626 G5496-60085) in an automated fashion using the standard protocol from the AssayMAP Bravo Platform
627 (Agilent Technologies). In short, Fe(III)-NTA cartridges were first primed with 100 µl of priming buffer
628 (100% ACN, 0.1% TFA) and equilibrated with 50 µL of buffer solution (80% ACN, 0.1% TFA). After
629 loading the samples into the cartridge, the cartridges were washed with an OASIS elution buffer, while
630 the syringes were washed with a priming buffer (100% ACN, 0.1% TFA). The phosphopeptides were
631 eluted with 25 µL of 1% ammonia directly into 25 µL of 10% FA. Samples were dried down with a
632 speed vacuum centrifuge and stored at -20 °C until LC-MS/MS analysis.
633

634 **Subcellular fraction of killifish brain by LOPIT-DC**

635 All the following steps were performed at 4°C, keeping samples on ice unless stated otherwise. Fresh
636 brains from adult (12 wph) and old (39 wph) killifish were pooled to reach ~150 mg of wet tissue weight
637 per biological replicate. A mixture of male and female fish was used. Fresh brain tissue was
638 subsequently transferred to a 15 mL Potter homogenizer (Fisher Scientific, 15351321) together with
639 7.5 mL of lysis buffer (LB) (250 mM sucrose, 10 mM HEPES ph 8.0, 2 mM MgAc, 2 mM EDTA)
640 supplemented with Protease Inhibitor (Roche, 11836170001) and homogenized with ~60 gentle strokes.
641 The brain homogenate was then transferred in a 15mL Falcon tube and treated with Benzonase (Merk,
642 70664) for 20 min at room temperature. An aliquot of 2.5 mL homogenate was collected for each sample
643 and stored at -80°C to be later processed for differential detergent extraction (see below). The remaining
644 5 mL were transferred to a 5 mL Eppendorf tube and centrifuged at 500 xg for 5 min at 4°C to remove
645 cell debris and unlysed cells. Subsequently, the clarified homogenate was centrifuged at 1000 xg for 13
646 min at 4°C and the resulting pellet was collected as the first subcellular fraction (01). Following one
647 additional centrifugation at 1000 xg for 7 minutes, the supernatant was then divided into 4 x 1.5 mL
648 Ultracentrifuge Tubes (Beckman) and processed for differential ultracentrifugation step with an Optima
649 TLX-BenchTop Ultracentrifuge (Beckman, 8043-30-1197), using a TLA55 rotor (Beckman, 366725),
650 using the following ultracentrifugation settings (Table 1):
651

<i>xg</i>	<i>Time</i>	<i>Fraction</i>	<i>Temperature</i>
3000	10'	02	4°C
5000	10'	03	4°C
9000	15'	04	4°C
12000	15'	05	4°C
15000	15'	06	4°C
30000	20'	07	4°C
79000	43'	08	4°C
120000	45'	09	4°C
—	—	10 (final supernatant, cytosol)	

		enriched)	
--	--	-----------	--

652

653 Table 1 : Ultracentrifugation settings for LOPIT-DC protocol

654

655 Pellets from each centrifugation step were resuspended in 50 μ L of PBS, and proteins were solubilized
656 by adding 50 μ L of 2x lysis buffer (200 mM HEPES pH 8.0, 100 mM DTT, 4% (w/v) SDS). For fraction
657 10 (cytosol enriched), 300 μ L was taken and supplemented with 300 μ L of 2x lysis buffer. All the
658 samples were then sonicated using a Bioruptor Plus (Diagenode) for 5 cycles with 60 sec ON and 30
659 sec OFF with max intensity, boiled for 10 min at 95°C, and a second sonication cycle was performed.
660 The solubilized proteins were reduced with 200mM DTT for 15 min at 45°C and alkylated using freshly
661 made 200mM IAA for 30 min at room temperature in the dark. Subsequently, proteins were precipitated
662 using cold acetone, dissolved in 1 M guanidine HCl in 100 mM HEPES pH8.0, and digested using LysC
663 and trypsin, as described in (64). The digested proteins were then acidified with 10 % (v/v)
664 trifluoroacetic acid and desalted using Oasis® HLB μ Elution Plate 30 μ m following manufacturer
665 instructions. The eluates were dried down using a vacuum concentrator and reconstituted in 5 % (v/v)
666 acetonitrile, 0.1 % (v/v) formic acid. Samples were transferred directly to MS vials, diluted to a
667 concentration of \sim 1 μ g/ μ L, and spiked with iRT kit peptides prior to analysis by LC-MS/MS.

668

669 **Differential detergent extraction**

670 All the following steps were performed at 4°C, keeping samples on ice unless stated otherwise. For
671 each replicate, 2.5 mL of brain homogenate was thawed on ice. After thawing, the homogenate was
672 centrifuged at 500 xg for 5 min at 4°C to remove debris. The supernatant was collected, and 64 μ L of
673 20% (v/v) IGEPAL Nonidet P-40 (Sigma) was added to reach an initial concentration of 0.5% (v/v).
674 The homogenate was then divided into 4x 1.5mL ultracentrifuge tubes and sonicated in a Bioruptor Plus
675 for 10 cycles with 30 min ON and 30 s OFF with max intensity at 24 °C. The homogenates were then
676 loaded into a TLA55 rotor and ultracentrifuged with an Optima TLX-BenchTop Ultracentrifuge at
677 100,000 xg for 5 min at 24°C. After ultracentrifugation, the supernatants were collected and stored as
678 “soluble” (S) fraction. The remaining pellets were resuspended in 1mL of buffer A (10 mM HEPES pH
679 8.0, 2 mM MgAc, 2 mM EDTA, 0.5% NP-40), samples were mixed by vortexing, and sonicated in a
680 Bioruptor Plus for 10 cycles with 30 s ON and 30 s OFF with max intensity at 24 °C. Samples were
681 then ultracentrifuged again at 100,000 xg for 5 min at 24°C. The supernatants (“F1”) were collected
682 and the remaining pellets were resuspended in 1mL of buffer B (10 mM HEPES pH 8.0, 2 mM MgAc,
683 2 mM EDTA, 0.5% NP-40, 0.25% SDS, 0.5% deoxycholic acid), mixed, sonicated, and centrifuged as
684 above. The supernatants (“F2”) were collected and the remaining pellets were resuspended in 1mL of
685 buffer C (10 mM HEPES pH 8.0, 2 mM MgAc, 2 mM EDTA, 0.5% NP-40, 2% SDS, 0.5% deoxycholic
686 acid), mixed, sonicated, and centrifuged as above. The supernatants (“F3”) and the remaining pellets
687 were collected. All the collected samples were stored at -80°C until further analysis.

688

689 **Data independent acquisition for proteome quantification**

690 Peptides were separated in trap/elute mode using the nanoAcquity MClass Ultra-High Performance
691 Liquid Chromatography system (Waters, Waters Corporation, Milford, MA, USA) equipped with
692 trapping (nanoAcquity Symmetry C18, 5 μ m, 180 μ m \times 20 mm) and an analytical column (nanoAcquity
693 BEH C18, 1.7 μ m, 75 μ m \times 250 mm). Solvent A was water and 0.1% formic acid, and solvent B was
694 acetonitrile and 0.1% formic acid. 1 μ L of the samples (\sim 1 μ g on column) were loaded with a constant
695 flow of solvent A at 5 μ L/min onto the trapping column. Trapping time was 6 min. Peptides were eluted
696 via the analytical column with a constant flow of 0.3 μ L/min. During the elution, the percentage of
697 solvent B increased nonlinearly from 0–40% in 120 min. The total run time was 145 min, including

698 equilibration and conditioning. The LC was coupled to an Orbitrap Exploris 480 (Thermo Fisher
 699 Scientific, Bremen, Germany) using the Proxeon nanospray source. The peptides were introduced into
 700 the mass spectrometer via a Pico-Tip Emitter 360- μm outer diameter \times 20- μm inner diameter, 10- μm
 701 tip (New Objective) heated at 300 °C, and a spray voltage of 2.2 kV was applied. The capillary
 702 temperature was set at 300°C. The radio frequency ion funnel was set to 30%. For DIA data acquisition,
 703 full scan mass spectrometry (MS) spectra with a mass range 350–1650 m/z were acquired in profile
 704 mode in the Orbitrap with the resolution of 120,000 FWHM. The default charge state was set to 3+.
 705 The filling time was set at a maximum of 60 ms with a limitation of 3×10^6 ions. DIA scans were
 706 acquired with 40 mass window segments of differing widths across the MS1 mass range. Higher
 707 collisional dissociation fragmentation (stepped normalized collision energy; 25, 27.5, and 30%) was
 708 applied, and MS/MS spectra were acquired with a resolution of 30,000 FWHM with a fixed first mass
 709 of 200 m/z after accumulation of 3×10^6 ions or after filling time of 35 ms (whichever occurred first).
 710 Data were acquired in profile mode. For data acquisition and processing of the raw data, Xcalibur 4.3
 711 (Thermo) and Tune version 2.0 were used.

712

713 **Data processing for MS-DIA samples**

714 Spectral libraries were created by searching the DIA or/and DDA runs using Spectronaut Pulsar (14.9.2
 715 and 15.3.2, Biognosys, Zurich, Switzerland). The data were searched against species-specific protein
 716 databases (Nfu_20150522, annotation nfuizeri_genebuild_v1.150922) with a list of common
 717 contaminants appended. The data were searched with the following modifications: carbamidomethyl
 718 (C) as fixed modification, and oxidation (M), acetyl (protein N-term), lysine di-glycine (K- ϵ -GG),
 719 phosphorylated tyrosine (T) and serine (S) and acetyl-lysine (K-Ac) as variable modifications for the
 720 respective PTMs enrichments. A maximum of 3 missed cleavages were allowed for K-Ac and K- ϵ -GG
 721 modifications, 2 missed cleavages were allowed for phospho enrichment. The library search was set to
 722 1 % false discovery rate (FDR) at both protein and peptide levels. DIA data were then uploaded and
 723 searched against this spectral library using Spectronaut Professional (v14.9.2 and 15.3.2) and default
 724 settings. Relative quantification was performed in Spectronaut for each pairwise comparison using the
 725 replicate samples from each condition using default settings, except the one displayed in Table 2:

726

727

<i>Dataset</i>	<i>Software version</i>	<i>Test</i>	<i>Data Filtering</i>	<i>Imputation</i>	<i>Normalization</i>
Aging proteome	15.3.2	Unpaired t-test	Q-value	Global Imputing	True, Automatic
LOPIT-DC	14.9.2	NA	Q-value percentile 0.2	Run Wise Imputing	True, Global
Detergent insolubility	15.4.2	NA	Q-value percentile 0.2	Run Wise Imputing	False
Proteasome Inhibition	14.9.2	Unpaired t-test	Q-value	Global Imputing	True, Automatic
PTMs - Ubiquitin	15.4.2	–	Q-value percentile 0.2	Global Imputing	True, Automatic

PTMs - Phosphorylation	15.4.2	–	Q-value percentile 0.2	Global Imputing	True, Automatic
PTMs - Acetylation	15.4.2	–	Q-value percentile 0.2	Global Imputation	True, Automatic

728

729 Table 2: Setting list used for MS data analysis on Spectronaut Software.

730

731 Candidates and report tables were exported from Spectronaut and used for downstream analysis.

732

733 Immunoblot

734 Killifish brains and cells treated for 24 hours with anisomycin (Cell Signaling Technology, 2222) were
 735 lysed following as described in “Sample preparation for total proteome and analysis of PTMs”. Protein
 736 concentration was estimated by Qubit assay (Invitrogen, Q33211), and 30 µg of proteins were used. 4×
 737 loading buffer (1.5 M Tris pH 6.8, 20% (w/v) SDS, 85% (v/v) glycerin, 5% (v/v) β-mercaptoethanol)
 738 was added to each sample and then incubated at 95 °C for 5 minutes. Proteins were separated on 4–20%
 739 Mini-Protean® TGX™ Gels (BioRad, 4561096) by sodium dodecyl sulfate-polyacrylamide gel
 740 electrophoresis (SDS-PAGE) using a Mini-Protean® Tetra Cell system (BioRad, Neuberger, Germany,
 741 1658005EDU). Proteins were transferred to a nitrocellulose membrane (Carl Roth, 200H.1) using a
 742 Trans-Blot® Turbo™ Transfer Starter System (BioRad, 1704150). Membranes were stained with
 743 Ponceau S (Sigma, P7170-1L) for 5 min on a shaker (Heidolph Duomax 1030), washed with Milli-Q
 744 water, imaged on a Molecular Imager ChemiDoc™ XRS + Imaging system (BioRad) and destained
 745 by 2 washes with PBS and 2 washes in TBST (Tris-buffered saline (TBS, 25 mM Tris, 75 mM NaCl),
 746 with 0.5% (v/v) Tween-20) for 5 min. After incubation for 5 min in EveryBlot blocking buffer (Biorad,
 747 12010020), membranes were incubated overnight with primary antibodies against RPS3 (Bethyl
 748 Laboratories, A303-840A-T) or α-tubulin (Sigma, T9026) diluted (1:1000) in enzyme dilution buffer
 749 (0.2% (w/v) BSA, 0.1% (v/v) Tween20 in PBS) at 4 °C on a tube roller (BioCote® Stuart® SRT6).
 750 Membranes were washed 3 times with TBST for 10 min at room temperature and incubated with
 751 horseradish peroxidase coupled secondary antibodies (Dako, P0448/P0447) at room temperature for 1 h
 752 (1:2000 in 0.3% (w/v) BSA in TBST). After 3 more washes for 10 min in TBST, chemiluminescent
 753 signals were detected using ECL (enhanced chemiluminescence) Pierce detection kit (Thermo Fisher
 754 Scientific, Waltham, MA, USA, #32109). Signals were acquired on the Molecular Imager
 755 ChemiDoc™ XRS + Imaging system and analyzed using the Image Lab 6.1 software (Biorad).
 756 Membranes were stripped using stripping buffer (1% (w/v) SDS, 0.2 M glycine, pH 2.5), washed 3
 757 times with TBST, blocked, and incubated with the second primary antibody, if necessary.

758

759

760 RNA isolation for RNA-Seq analysis

761 Individual brains from the fish were collected and snap-frozen in liquid nitrogen. The protein amount
 762 was estimated based on fresh tissue weight (assuming 5% of protein w/w), and ice-cold 1x PBS with
 763 protease/ phosphatase inhibitors (Roche, 11836170001, 4906837001) was added accordingly to a final
 764 concentration of 2 µg/µL. Samples were then vortexed (5 times) before sonication (Bioruptor Plus) for
 765 10 cycles (60 sec ON/30 sec OFF) at the high setting, at 4 °C. The samples were then centrifuged at
 766 3000 xg for 5 min at 4 °C, and the supernatant was transferred to 2 mL Eppendorf tubes. 1.5 mL of ice-
 767 cold Qiazol (Qiagen, 79306) reagent was added to 150 µL of homogenate, vortexed five times, and
 768 snap-frozen in liquid nitrogen. On the day of the experiment, samples were thawed on ice, vortexed five
 769 times, and incubated at room temperature for 5 min before adding 300 µL of chloroform. Samples were

770 mixed vigorously, incubated for 3 min at room temperature, and centrifuged at 12000 xg for 20 min at
771 4 °C. The upper aqueous phase (600 µL) was carefully transferred into a fresh tube, and the remaining
772 volume (phenol/chloroform phase) was kept on ice for DNA isolation. The aqueous phase was mixed
773 with 1.1 volume of isopropyl alcohol, 0.16 volumes of sodium acetate (2 M; pH 4.0), and 1 µL of
774 GlycoBlue (Invitrogen, AM9515) to precipitate RNA. After 10 min incubation at room temperature,
775 samples were centrifuged at 12000 xg for 30 min at 4 °C. The supernatant was completely removed,
776 and RNA pellets were washed by adding 80% (v/v) ethanol and centrifuging at 7500 xg for 5 min at 4
777 °C. The washing steps were performed twice. The resulting pellets were air-dried for no more than 5
778 min and dissolved in 10 µL nuclease-free water. To ensure full dissolution of RNA in water, samples
779 were then incubated at 65 °C for 5 min, before storage at -80 °C.

780

781 **RNA-Seq library preparation**

782 Sequencing of RNA samples was done using Illumina's next-generation sequencing methodology (66).
783 In detail, quality check and quantification of total RNA was done using the Agilent Bioanalyzer 2100
784 in combination with the RNA 6000 pico kit (Agilent Technologies, 5067-1513). Total RNA library
785 preparation was done by introducing 500 ng total RNA into Illumina's NEBNext Ultra II directional
786 mRNA (UMI) kit (NEB, E7760S), following the manufacturer's instructions. The quality and quantity
787 of all libraries were checked using Agilent's Bioanalyzer 2100 and DNA 7500 kit (Agilent
788 Technologies, 5067-1506).

789

790 **RNA-Seq sequencing**

791 All libraries were sequenced on a NovaSeq6000 SP 300 cycles v1.5; paired-end 151 bp (one pair for
792 each of the projects). Total RNA libraries were pooled and sequenced in three lanes. Small RNA
793 libraries were pooled and sequenced in one lane. Sequence information was extracted in FastQ format
794 using Illumina's bcl2FastQ v2.20.0.422, against the *Nothobranchius furzeri* reference genome
795 (Nfu_20150522, annotation nfuzei_genebuild_v1.150922). Alignment to the reference genome was
796 performed using STAR (67) with the following parameters: --outSAMmultNmax 1 --
797 outFilterMultimapNmax 1 -- outFilterMismatchNoverLmax 0.04 --sjdbOverhang 99 --alignIntronMax
798 1000000 -- outSJfilterReads Unique. The deduplication step was performed using the umi_tool v1.1.1
799 (68), using the following parameters: extract --bcpattern= NNNNNNNNNNNN', `dedup --chimeric-pairs
800 discard --unpaired-reads discard -- paired.

801

802 **RNA-Seq quantification and differential expression**

803 RNA-Seq data were then processed as follows: quantification was performed using featurecounts v2.0.3
804 (69) with the following parameters -s 2 -p -B --countReadPairs. Differential expression analysis was
805 performed using the DESeq2 package (v1.34.0) (70). Raw count data were normalized using the
806 transcript per million strategy.

807

808 **Ribo-Seq library preparation**

809 Ribosome profiling libraries were prepared following previously published protocol with modifications
810 (24). 10~15 brain samples from fish were combined and lysed frozen using Cryo-Mill (Retsch, MM301)
811 in the presence of 1ml of lysis buffer (20 mM Tris-HCl pH 7.5, 140 mM KCl, 5 mM MgCl₂, 1 mM
812 DTT, 100 µg/ml Cycloheximide, 1% Triton X-100, and 1 X Protease Inhibitor). Lysed powder was
813 quickly thawed in a water bath at room temperature and spun at 21,000 g for 15 minutes at 4 °C to clear
814 lysate. RNase I (Invitrogen, AM2294) was added to 0.4U/µg of RNA and incubated at 25 °C for 45
815 minutes. Digestion was stopped by adding 0.4U/µg of SUPERaseIn RNase Inhibitor (Invitrogen,
816 AM2696). RNase-treated lysate was layered on 900 µl sucrose cushion buffer (20 mM Tris-HCl

817 pH 7.5, 140 mM KCl, 5 mM MgCl₂, 1 mM DTT, 100 µg/ml Cycloheximide, 0.02U/µl SuperaseIn, 1M
818 Sucrose), and spun at 100,000 rpm for 1 hour at 4 °C in TLA100.3 rotor. Resulting ribosome pellet was
819 resuspended in 250 µl of lysis buffer with SuperaseIn and RNA was extracted using TRIzol reagent
820 (Invitrogen, 15596026) following manufacturer's protocol. 27-34bp fragments were isolated from
821 denaturing gel, ligated to adapter (NEB, S1315S), and ribosomal RNA was removed using RiboCop
822 (Lexogen, 144.24) mixed with custom depletion DNA oligos (Table 4). Remaining fragments were
823 reverse transcribed, circularized, and PCR amplified following the steps described previously (71).
824 Barcoded samples were pooled and sequenced using Hiseq 4000 (Illumina).

825

826 **Imaging**

827

828 **Cryo-sections preparation and free-floating immunofluorescence**

829 To prepare brain cryo-sections for free-floating immunofluorescence from 5 wph and 39 wph old
830 killifish, brains were dissected and fixed ON in a solution of 4% paraformaldehyde PFA in PBS at 4°C.
831 The samples were then equilibrated in a 30% sucrose solution ON at 4° and subsequently embedded in
832 cryo-protectant (Tissue -Tek O.C.T. Compound; Sakura Finetek, USA). Tissue slices of 50µm
833 thickness were cut at a cryostat (Leica) and stored on glass slides (Thermo Fisher Scientific, USA).
834 Free-floating immunofluorescence experiments were performed by adapting previous protocols for
835 classical on-slide immunofluorescence (72). Briefly, the sections were washed in PBS to remove the
836 cryo-embedding medium and detached from the glass slide. The sections were then placed in 24-wells
837 and performed two additional washes in PBS for 5 min each. Afterward, an acid antigen retrieval step
838 (10 mM Tri-sodium citrate dihydrate, 0.05% tween, at pH 6) was performed by bringing the solution to
839 boiling point in a microwave and adding 50ml of it in each well, leaving the solution for 5 minutes.
840 This step was repeated two times.. 500 µl of blocking solution (5% BSA, 0.3% Triton-X in PBS) was
841 then applied for 2 h. Primary antibodies (Phospho-Tau AT100, NeuN or Lamp1 Table 3) at the proper
842 dilution were added in a solution of 1% BSA, 0.1% triton in PBS, and left overnight at 4°C in slow
843 agitation on a rocker. Next day, the proper secondary antibodies (Table 3) at a 1:500 dilution were used
844 in the same solution. After 2h of incubation, slices were washed three times with PBS, counter-stained
845 with a solution 1:10000 of Hoechst 33342 (Invitrogen, USA) for two minutes and manually mounted
846 under a stereomicroscope on Superfrost Plus glass slides (Thermo Fisher Scientific, USA). Finally,
847 Fluoroshield mounting medium (Sigma, USA) was used and slices were covered with a coverglass
848 (Thermo Fisher Scientific, USA).

849

850 **Image acquisition**

851 Imaging of lysosomal staining was performed with a Zeiss scanning confocal microscope (LSM900,
852 Zeiss, Germany) equipped with an Airyscan module. Nine consecutive z planes with a step of 300nm
853 were acquired with a 63x oil immersion objective (Plan-Apochromat 63x/1.4 Oil DIC M27, Zeiss,
854 Germany) at a resolution of 2186x2186 pixels with the use of Airyscan. Images were then deconvoluted
855 in the Zeiss Zen blue 3.7 suite using the Fast Iterative algorithm and exported as tiff for further analysis
856 in Imaris (Bitplane, UK).

857 Samples processed for Tau stainings were imaged with an Axio Imager Z.2 (Zeiss, Germany) equipped
858 with an Apotome slide using a 63x oil immersion objective (Plan-Apochromat 63x/1.4 Oil DIC M27,
859 Zeiss, Germany). Z-stacks were realized by acquiring five consecutive z-planes at an interval of 1
860 micron. Images were then processed in imageJ (Fiji).

861

862 **Lysosomes morphological analysis**

863 To analyze the change in morphology of lysosomes in aging, we analyzed nine 5 wph samples and
 864 twelve 39 wph samples. To study morphological changes in case of proteostasis alteration, samples
 865 from six bortezomib-treated animals and six controls (DMSO treated) were analyzed. Tiff images were
 866 loaded in Imaris (Bitplane, UK) to recreate a 3D rendering of the samples. A version of the ‘Surfaces’
 867 algorithm was created, optimizing the settings to realize an optimal mask of single lysosomes. Statistics
 868 obtained (Area, Volume, Mean intensity, and Sphericity) were extracted, and mean values for each
 869 animal were calculated. Data significance was tested using a two-tails T-test.

870

871 **Mean fluorescence intensity analysis**

872 To analyze differences in the amount of Tau phosphorylation between young (5 wph) and old (39 wph)
 873 *Nothobranchius furzeri* brain samples, we performed mean fluorescence intensity (MFI) analysis in the
 874 free license software ImageJ (Fiji). Since Tau is a neuronal protein, and the number of neurons between
 875 young and old animals varies, we normalized the MFI of Tau staining over the MFI of NeuN, a
 876 neuronal-specific marker, in order to render the Tau MFI proportional to the number of neurons. Images
 877 were opened in ImageJ (Fiji), and median filtering (1px radius) was applied. The average intensity
 878 projection was realized, and MFI for the green channel (Tau) and red channel (NeuN) was measured
 879 and reported in an Excel table. Tau MFI for each animal was divided by the corresponding NeuN MFI,
 880 and the significance of the results was tested by a two-tails T-test.

881

882

883

Primary Antibody	Producer	Catalog Number	Type	Working dilution
Lamp1	Abcam	Ab24170	Polyclonal Rabbit	1:500
NeuN	Abcam	Ab177487	Monoclonal Rabbit	1:500
Phospho-Tau AT100	Thermo Fisher Scientific	MN1060	Monoclonal Mouse	1:400
Secondary Antibody				
AlexaFluor 488 anti-Rabbit	Invitrogen	A11001	Goat IgG	1:500
AlexaFluor 568 anti-Rabbit	Invitrogen	A11011	Goat IgG	1:500
AlexaFluor 488 anti-Mouse	Invitrogen	A11004	Goat IgG	1:500

884

885 Table 3: List of antibodies utilized in this work

886

Oligo #1	GGCCGTTACCGGCTCACACCGTCCATGGGATGAGC/3BioTEG/
Oligo #2	CGGGCGAGACGGGCCGGTGGTGCGCCCGGAAC/3BioTEG/
Oligo #3	CGCCTCCCCGCTCACCGGGTAAGTGAAAAACGATAAGAG/3BioTEG/
Oligo #4	GCACGCGCCGGGCGCTTGACACCAGAACCGAGAGC/3BioTEG/

887

888

Table 4: List of DNA oligonucleotides used for ribosomal RNA depletion

889

890 Data analysis

891

892 Protein subcellular localization by LOPIT-DC

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

908 Differential detergent extraction

909

910

911

912

913

914

915

916

917

918

919

920

921

922

922 Modified peptide abundance correction

923

924

For each enrichment, PTMs report tables were exported from Spectronaut. To correct the quantities of modified peptides for underlying changes in protein abundance across the age groups compared,

925 correction factors were calculated using the aging proteome data. For each condition and protein group,
926 the median protein quantity was calculated and then divided by the median protein quantity in the young
927 (5 wph) age group. Each modified peptide was matched by protein identifier to the correction factor
928 table. If a modified peptide was mapped to 2 or more proteins, the correction factor was calculated using
929 the sum of the quantity of these proteins. Further, the correction was carried out by dividing peptide
930 quantities by the mapped correction factors, and log₂ transformed (see Figure S4B). Differences in
931 peptide quantities were statistically determined using the t-test moderated by the empirical Bayes
932 method as implemented in the R package limma (75).

933

934 **Kinase activity prediction from phosphoproteome data**

935 Kinase activity prediction was calculated using the Kinase library ([https://kinase-](https://kinase-library.phosphosite.org/ea?a=de)
936 [library.phosphosite.org/ea?a=de](https://kinase-library.phosphosite.org/ea?a=de)), (76) using the differential expression-based analysis and default
937 parameter.

938

939 **GO enrichment analysis**

940 Gene Set Enrichment Analysis (GSEA) was performed using the R package clusterProfiler (77), using
941 the function gseGO. Briefly, *Nothobranchius furzeri* protein entries were mapped to the human gene
942 name orthologues and given in input to the function to perform the enrichment. For GO term
943 overrepresentation analysis (ORA), the topGO R package was used.

944

945 **Identification of conserved PTMs sites**

946 For the *Nothobranchius furzeri* proteins involved in neurodegenerative diseases (Figure S5I), a local
947 alignment was performed with protein BLAST(v2.12.0+) (78) with default parameters against the
948 RefSeq human proteome (Taxon ID:9606). The top 10 hits from the BLAST search were retrieved, and
949 each modified residue was mapped into the local alignment to identify the corresponding position in
950 the human proteins. Each modified peptide was then considered conserved if at least one of the top 10
951 hits from the BLAST alignment had a corresponding residue in the modified amino acid position.

952

953 **Calculation of protein-transcript decoupling and multiple linear regression**

954 For aging brain proteome data and proteasome impairment samples, protein-transcript decoupling
955 values were calculated as the difference in log₂ fold changes between proteome and transcriptome. A
956 null distribution was fitted on the decoupling values using the R package fdrtool (79). Q-value < 0.1
957 was used as a threshold to reject the null hypothesis. The decoupling values from each protein-transcript
958 pair were used as response variables in a multiple linear regression model. Predictors for the model
959 were retrieved as follows: protein quantities were calculated as the median log₂ protein quantity across
960 all replicates from the proteomics DIA data. Protein quantities are estimated using the median peptide
961 abundance as calculated by the Spectronaut software. mRNA abundance values were defined as the
962 median log₂(TPM) across all samples from the RNA-Seq aging dataset. Biophysical parameters were
963 calculated for each protein with the R package Peptides. Protein half-life values were taken from mouse
964 cortex data from (16). The percentage of gene GC content was obtained from ENSEMBL Biomart
965 (v108) (80), mapping ENSEMBL annotation against the *Nothobranchius furzeri* reference genome
966 (Nfu_20150522, annotation nfurzeri_genebuild_v1.150922) using bedtools (81). Multiple linear
967 regression models were then performed using the `lm` base R function by keeping only complete and
968 unique observations from the matrix generated. Features were scaled for each dataset, and a multiple
969 linear regression model without intercept was fitted to the data.

970

971

972 **Data integration**

973 Log₂ fold changes (for PTMs), ΔDIS (for detergent insolubility), or protein-transcript decoupling score
974 values were used as input for a GSEA analysis based on GO cellular component terms using the gseGO
975 function from the clusterProfile (77) R package with the following parameters minSize = 5 and maxSize
976 = 400. For each GSEA, the normalized enrichment scores (NES) were taken and arranged in a matrix
977 with different GO terms as rows and different datasets as columns. To visualize the relationship between
978 the dataset, a principal component analysis was performed on the matrix. Missing GO terms in a given
979 dataset were imputed as 0 values. The sum of the scores on the first two principal components was used
980 to extract the most strongly affected GO terms from the combined integration of all the datasets.

981

982 **Mitochondrial proteome composition**

983 To calculate age-related changes in mitochondrial proteome composition (Figure 2H), raw DIA files
984 coming from fraction 02 of the LOPIT-DC experiment were re-analyzed in Spectronaut (v16.2), using
985 the same parameters as the other LOPIT-DC experiment. Fraction 02 represents the fraction where
986 mitochondrial proteins are sedimenting in the LOPIT-DC experiment and, therefore, strongly enriched
987 for mitochondrial proteins (Figure S3C-D). From the protein quantity matrix, mitochondrial proteins
988 (according to Mitocarta3.0 annotation (82)) were extracted, and their quantities log₂ transformed and
989 normalized by median centering. To detect changes in composition, a linear model on the log₂
990 mitochondrial-centered values was implemented between the two age groups with the R package limma
991 (75).

992

993 **Ribo-seq data processing and analysis**

994 Data processing and analysis was based on previously published protocol (24). Adapter sequences were
995 removed from demultiplexed sequencing reads using Cutadapt v.1.4.2 (83), followed by removal of the
996 5' nucleotide using FASTX-Trimmer. Reads mapping to ribosomal RNAs were removed using Bowtie
997 v.1.3.1 (84). Remaining reads were aligned to reference libraries that consisted of coding sequences
998 containing 21 nucleotides flanking upstream of the start codon and downstream of the stop codon. To
999 maximize unique mapping, a reference library was constructed using the longest transcripts for every
1000 22757 genes. Bowtie alignment was performed using the following parameters: -y -a -m 1 -v 2 -norc -
1001 best -strata. A-site offset was estimated using riboWaltz (85), and fragment lengths that do not exhibit
1002 3-nucleotide periodicity were removed. Pause scores at each position were calculated by dividing the
1003 number of reads at each position by the average number of reads within the internal part of the transcript,
1004 excluding the first and last 20 codons. Positions with increased pausing during aging were identified
1005 following the previously published method (24). Briefly, for 6749 transcripts with sufficient coverage
1006 (>0.5 reads/codon and >64 reads/transcript) in all age groups, we used a two-tailed Fisher's exact test
1007 to compare each position (codon) between age groups to identify positions with statistically significant
1008 changes (Benjamini-Hochberg adjusted P-value < 0.05). These positions were further filtered to include
1009 positions with odds ratio greater than 1, pause score of the older sample greater than the pause score of
1010 younger sample, reads in the oldest sample greater than the average number of reads across the
1011 transcript, and a position in the internal part of the transcript to only select sites with high-confidence
1012 age-dependent changes in pausing. To visualize amino acids enriched in age-dependent pausing sites,
1013 we used the weighted Kullback Leibler method (86) using the frequency of each amino acid in coding
1014 sequences as background. For metagene analysis around age-dependent pausing sites, reads were first
1015 aligned to these sites and normalized by dividing reads at each codon by the average reads per codon
1016 within the analysis window to control for differences in expression and coverage. Mean and
1017 bootstrapped 95% confidence intervals of these normalized values were plotted. Only positions with
1018 sufficient coverage (reads/codon>0.5) in the analysis window were included. To identify sites with

1019 disome formation, we first identified sites with strong pausing in the old sample (pause score >6). Then,
1020 we calculated the average ribosome density of two regions for young and old samples; 1) analysis
1021 window (40 codons up/downstream from strong pause site) and 2) between 8 and 12 codons upstream
1022 from strong pause site (approximate position of trailing ribosome). Sites with higher ribosome density
1023 in 2) were identified as disome sites, and disomes sites unique to old samples were plotted. For
1024 comparisons to proteomics data sets, we included all sites with statistically significant changes
1025 (Benjamini-Hochberg adjusted P-value < 0.05) and used log₂ of pause score ratio (Old/Young).
1026 For translation efficiency analysis, RNA-seq data was re-aligned to the same reference library used for
1027 Ribo-seq to compare transcript abundance. Changes in translation efficiency were calculated using
1028 DESeq2 (70), using the following design ~assay + condition + assay:condition, where assay indicates
1029 the different counts from RNA-Seq and Ribo-Seq respectively, and condition indicated the different
1030 age groups.

1031

1032 **Estimates of mRNA half-life variations**

1033 Exonic coordinates of protein-coding genes were extracted from the annotation
1034 *nfurzeri_genebuild_v1.150922*. Exonic and intronic read counts were obtained following the procedure
1035 suggested by (31). To this end, exonic coordinates were flanked on both sides by 10 nt and were grouped
1036 by gene. Intronic coordinates were obtained by subtracting the exonic coordinates from the gene-wise
1037 coordinates. For each gene, exonic and intronic read counts were obtained using the *htseq-count*
1038 function from HTSeq v2.0.2 (87) with the parameter *-m* set to *intersection-strict* to consider only reads
1039 that strictly fall within an exon or an intron. Additionally, in each sample, genes with less than 10 reads
1040 on both exons and introns were ignored (read counts set as missing values) in order to be robust against
1041 noisy estimates based on low read counts. Lastly, the log-transformed exonic-to-intronic read count
1042 ratio *r* was computed for each gene and sample as:

1043

$$1044 \quad r = \text{Log}_2(\text{exonic counts} + 1) - \text{Log}_2(\text{intronic counts} + 1)$$

1045

1046 Gene-specific biases such as exonic and intronic lengths and GC content can affect exonic and intronic
1047 read counts. These biases cancel out when ratios between samples are considered, as they are typically
1048 multiplicative (31). The ratio between mRNA half-life in sample *s₁* and sample *s₂* is then estimated
1049 as:

1050

$$1051 \quad \left| \text{Log}_2\left(\frac{\text{mRNA half-life } s_1}{\text{mRNA half-life } s_2}\right) = \frac{r_1}{r_2} \right.$$

1052

1053 **Estimates of protein synthesis rate**

1054 To estimate *k_i*, 5'-UTRs sequences were retrieved from the *Nothobranchius furzeri* reference genome
1055 (*Nfu_20150522*, annotation *nfurzeri_genebuild_v1.150922*). The masked FASTA genome sequences
1056 were parsed using *bedtools* (81). The translation starting codon "ATG" was identified from the 'CDS'
1057 features from the GFF file. The region around the starting codon was extracted with +6 nucleotide
1058 upstream and +4 nucleotide downstream to match the pattern "NNNNNNATGNN". Only valid
1059 sequences (without ambiguous nucleotides) with an ATG starting codon in the correct position were
1060 retained. 91% of the transcript annotated in the GFF file had a valid translation initiation region as
1061 described above. The *k_i* was then estimated using the dinucleotide position weight matrix from (34). In
1062 case a single transcript had multiple starting sites, the *k_i* values were summarized by taking the median
1063 value. This led to the estimate of *k_i* for 59129 transcripts. Estimated protein synthesis rates were
1064 calculated as in (32, 33). More in detail, the authors described the estimated synthesis rate as:

1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108

$$Q = mRk_i [1 - (L / ((k_e / (k_i R)) + (L - 1)))]$$

where Q refers to the estimated synthesis rate, m refers to individual mRNA expression level obtained from the median across sample $\log_2(\text{TPM})$ from RNA-Seq data and normalized between 0 and 1, R represents the total amount of available ribosomes, k_i indicates an mRNA-specific translation initiation rate as computed above and normalized between 0 and 1, L is the number of codons occupied by one ribosome, set to 10 (based on the average length of a ribosome footprint), and k_e is the termination rates arbitrarily set to 1. Estimated synthesis rates were then computed for different values of R ranging from 1.3 to 0.

1109 **Supplementary text:**

1110

1111 Aging can influence different aspects of protein homeostasis. To obtain an unbiased characterization of
1112 the effect of aging on the brain proteome we employed a multi-layered approach to interrogate major
1113 modes of protein regulation. We generated datasets describing changes in protein and mRNA levels,
1114 protein subcellular localization, detergent insolubility, and post-translational modifications (PTMs) in
1115 the aging brain of killifish (Figure 2A and S3A). First, we captured proteome-wide variation in
1116 subcellular localization using an approach based on differential centrifugation coupled with quantitative
1117 mass spectrometry (LOPIT-DC) (18) and analyzed pools of adult (12 weeks post-hatching = wph) and
1118 old (39 wph) killifish brains (Figure S3B, Table S2). We used a list of well-annotated organelle markers
1119 (88) to evaluate organelle separation by LOPIT-DC (Figure S5A and S3C, D) and to confirm the
1120 reproducibility of organelles sedimentation between adult and old brains (Figure S3E). We then
1121 employed a tailored statistical approach (see methods, Figure S3F) to identify age-dependent changes
1122 in protein sedimentation profiles (Figure S5B, Table S2). The most prominent changes affected multiple
1123 mitochondrial and lysosomal proteins among others, including the mitochondrial transporters
1124 SLC25A32 and SLC25A18, and the lysosomal and vesicle trafficking proteins RAB14 and CCZ1
1125 (Figure S5C). We interpret these alterations of sedimentation as an indication of partial reorganization
1126 of the mitochondrial and lysosomal proteome during aging that correlates with the well-described
1127 dysfunction of these organelles during aging and neurodegenerative diseases.

1128

1129 In parallel, we used the same pools of samples to assess age-dependent changes in protein solubility.
1130 We complemented our previous analysis of SDS insoluble aggregates in the killifish aging brain (6)
1131 with a more fine-grained analysis of protein solubility. Thus, we exposed brain homogenates to a series
1132 of detergent combinations of increasing strength, separated soluble and insoluble fractions by
1133 ultracentrifugation (as described in (17), Figure S2A, Table S2), and quantified protein abundances
1134 across fractions using mass spectrometry. Principal component analysis showed reproducible detergent-
1135 based fractionation in adult and old brains (Figure S2B) and GO enrichment analysis confirmed the
1136 expected partitioning of cellular components as a function of detergent strength (Figure S2C and S2D).
1137 In agreement with previous findings from other species (11, 89) and the spontaneous age-related
1138 accumulation of protein aggregates in killifish brain (5–7), we observed an overall increase of protein
1139 detergent-insolubility in old samples (Figure S2E). By comparing detergent insolubility profiles
1140 between adult and old brains (Figure S2F-G), we identified 410 protein groups changing detergent
1141 insolubility with aging (Figure S5D, Table S2). While many of these proteins exhibited increased
1142 insolubility to detergents in old brains, there were instances where aging was linked to decreased
1143 insolubility to detergents. This indicates that factors other than protein aggregation, such as alterations
1144 in protein interactions or localization, could be responsible for the observed changes in detergent
1145 insolubility.

1146


1147 Next, we examined the effects of brain aging on multiple PTMs, using a sequential enrichment strategy
1148 followed by quantification of age-dependent changes in protein ubiquitylation, acetylation, and
1149 phosphorylation in the aging brain (Figure S4A, Table S3). We quantified PTM-carrying peptides
1150 normalized for protein changes (see methods, Figure S4) and identified age-related changes for 534
1151 phosphorylated, 618 ubiquitylated, and 190 acetylated peptides ($P < 0.05$, Figure S5E). The general
1152 increase in the number of affected PTM peptides with aging emphasized its overall impact on the
1153 proteome beyond protein abundance (Figure S5E-F). Integration of phosphorylation data with
1154 experimentally derived kinase-substrate relationships (76) indicates a remodeling of kinase signaling in
1155 the aging brain. Besides an increased activity (i.e., increased phosphorylation of predicted targets) for
1156 kinases involved in the regulation of immune responses, we reported enhanced activity for kinases of

1157 the protein kinase C family, e.g., PKN1, PKN2, PKCA, whose hyperactivation is linked to Alzheimer's
1158 disease (90,91,92). Our data also reveals the decreased activity of kinases responsible for the
1159 phosphorylation of splicing factors and other RNA processing proteins, e.g. CDC2-like kinases 2 and 4
1160 (CLK2 and CLK4, Figure S5G-H). These data suggest a convergence between aging and
1161 neurodegeneration concerning altered signaling pathways in the brain and hints at dysfunctional RNA
1162 processing in the aging brain.

1163
1164 To more systematically investigate the convergence between brain aging and neurodegenerative
1165 diseases, we queried our datasets for killifish orthologs of proteins encoded by genes that have been
1166 genetically linked to neurodegeneration in humans (Table S4). We found several of these proteins to be
1167 affected by aging in killifish in at least one of the proteomic datasets analyzed (Figure S5I). These
1168 include changes in subcellular fractionation and detergent insolubility (Figure S6A-B), as well as 23
1169 PTM sites conserved between killifish and humans (Figure S6C-D-E). The microtubule-associated
1170 protein Tau (MAPT) was notably affected by aging across multiple proteomic layers. MAPT showed a
1171 prominent increase in detergent insolubility in old brains (Figure S5D), an alteration associated with
1172 human aging and neurodegenerative diseases (93–95). Additionally, we detected an age-dependent
1173 increase in phosphorylation and ubiquitylation of conserved residues in the microtubule-binding
1174 domain (MBD) of MAPT, a region sensitive to PTMs and associated with Tau pathological aggregation
1175 (Figure S5J and S6D) (96), (95, 97). We validated the spontaneous increase of MAPT/Tau
1176 phosphorylation in old killifish brains using immunofluorescence staining for a conserved
1177 phosphorylated epitope of Tau (AT100) (Figure S5K).

1178
1179 Together, our analyses comprehensively establish how aging affects the brain proteome along multiple
1180 axes beyond protein abundance, using a consistent model organism and age groups. This thorough
1181 characterization of the proteome reveals several potential connections between aging, specific
1182 molecular events, and genetic factors associated with neurodegeneration, which are relevant to humans.
1183 To make this resource easily accessible to the scientific community, we have developed a web
1184 application at xxxxxx

1185
1186
1187
1188



1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

Figure S1: Proteome and transcriptome characterization of the killifish aging brain. A) Principal component analysis of proteomics data. B) Correlation heatmap between samples from the aging brain proteome data. Pairwise Pearson's R correlation coefficient was calculated on the log₂ transformed protein abundances. C) Boxplot displaying the distribution of log₂ transformed and normalized protein abundances. D) Volcano plot highlighting significant protein abundance changes in the aging brain (39 wph vs. 5 wph). Dashed lines indicate the threshold used to select differentially abundant proteins (absolute log₂ FC > 0.58 and -log₁₀ Q-value < 0.05). E) Principal component analysis of transcriptomics data. F) Correlation heatmap between samples from the aging brain transcriptome data. Pairwise Pearson's R correlation coefficient was calculated on the log₂ transformed transcript per million reads (TPM). G) Boxplot displaying the distribution of log₂ transformed and normalized transcript counts (TPM). H) Volcano plot highlighting significant transcript abundance changes in the aging brain (39 wph vs. 5 wph). Dashed lines indicate the threshold used to select differentially expressed genes (absolute log₂ FC > 0.58 and -log₁₀ Adjusted P-value < 0.05). For displaying purposes, the X-axis range was limited to a -10:10 range leading to the exclusion of 1 gene. I) 2-D density plot showing the correlation between protein-transcript decoupling during aging in this study, displayed on the y-axis, and protein-transcript decoupling described in (6) (x-axis). Related to Figure 1 and Table S1.





Figure S2: Protein detergent insolubility changes in the killifish aging brain. A) Scheme of the differential detergent extraction experiment. The protocol was adapted to brain tissue from ((17) see methods). B) Principal component analysis based on proteomics data from fractions obtained by differential detergent extraction. C) K-means clustering of detergent insolubility profiles. On the y-axis, the log₂ protein quantity relative to the soluble “S” fraction, each profile represents the median across both conditions and (N=4 pools) replicates. D) GO enrichment overrepresentation analysis (ORA) of proteins assigned to each cluster against the rest of the identified proteome. On the x-axis, the $-\log_{10}$ of the adjusted P-value (Holm correction) of the Fisher’s Test is reported. Colors refer to the different clusters displayed in panel C. E) Boxplot depicting detergent insolubility profiles for all the proteins quantified across age groups. The y-axis indicates the log₂ transformed value of protein quantity in each fraction relative to the soluble (S) fraction. Asterisks indicate the results of a two-sample Wilcoxon test. F) Computational strategy used for calculating differences in detergent insolubility profile across age groups. A MANOVA test was performed on each protein profile to detect significant changes in the multivariate mean between 12 wph (adult) and 39 wph (old samples), N=4 pools per age group. The detergent insolubility score (DIS) was calculated by summing the log₂ protein quantity (relative to the soluble S fraction). Higher DIS indicate proteins that are relatively more abundant in insoluble fractions (F1:F3) than the soluble one (S). G) Example profiles of top hits proteins displaying changes in detergent insolubility with aging. EIF3B is an example of a protein that displays decreased detergent insolubility with age, while SULT2A1 displays increased detergent insolubility with age. For the left panel, the y-axis represents the log₂ protein quantity in each fraction relative to the first soluble (S) fraction. Dark lines indicate the median between replicates, while shaded areas represent 50% of the replicate distribution, N=4 pools per age group. On the right panel, boxplots show the Detergent insolubility score (calculated as the sum of the log₂ protein quantity relative to the first soluble (S) fraction) for the same proteins. Related to Figure 2, S5 and Table S2. *P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.


1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226



1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243

Figure S3: Subcellular fractionation of the killifish aging brain by LOPIT-DC. A) Survival curves of *Nothobranchius furzeri* MZM-0410 strain in captivity (data from (98)). The survival of *Nothobranchius furzeri* was investigated by tracking the occurrence of deaths starting at the age of 5 weeks post-hatching (wph), which corresponds to sexual maturity. This study includes data from four age groups highlighted by vertical dashed lines. The analyzed strain was derived from the wild with a median lifespan of 7-8 months. B) Scheme of the LOPIT-DC experiment. The protocol was adapted to brain tissue from (18) see methods for details. C-D) Organellar markers protein profiles from LOPIT-DC. The x-axis indicates the different fractions. The y-axis indicates protein abundance estimates derived from label-free Data Independent Acquisition mass spectrometry. Protein quantities were normalized by dividing the protein quantity in each fraction by the sum of the protein quantity along fractions. Each profile represents the median across replicates (N=4 pools). The median profiles of each organelle are highlighted by a colored solid line. Profiles obtained from adult (12 wph, panel C) and old (39 wph, panel D) fish are shown. E) Principal component analysis for different organellar markers in the LOPIT-DC fractions. Organellar markers from 12 wph (pink) and 39 wph (green) are shown. Each dot represents the median profile across (N=4 pools) replicate for each condition. F) Computational strategy used to identify age-related changes in protein sedimentation profiles. Related to Figure 2, Figure S5 and Table S2.

1244



1245

1246

1247

1248

1249

1250

1251

1252


1253

1254

1255

1256

Figure S4: Analysis of protein post-translational modifications in the killifish aging brain. A) Workflow for the enrichment of post-translational modified peptides from in killifish brain. B) Correction strategy for detecting stoichiometric changes in post-translationally modified peptides. Correction factors were computed for each protein and condition relative to the 5 wph (young) age group. Quantities of the modified peptides were divided by the corresponding protein correction factor, and age-related changes were tested using *limma* (75). C-H) Relationship between age-related abundance changes of modified peptides vs. corresponding protein, before (left panels) and after (right panels) correction. The red text indicates the test results for the association between paired samples using Pearson's product-moment correlation coefficients. Related to Figure 2, Figure S5 and Table S3.




1257

Figure S5: Aging affects protein subcellular localization, detergent insolubility and PTMs A) Organelle markers protein profiles from LOPIT-DC (12 wph). The x-axis indicates the different fractions of the LOPIT-DC experiment. The y-axis indicates protein distribution across fractions. The median profiles of each organelle are highlighted by a colored solid line. B) Scatterplot depicting protein relocation scores in the aging killifish brain. The x-axis indicates the median replicate Euclidean distance of the profiles between the two conditions. Y-axis indicates the $-\log_{10}$ P-value of the Hotelling T-squared test, between adult and old profiles ($N=4$ pools per age group). C) Examples of sedimentation profiles for selected proteins with altered subcellular fractionation profiles. In each of the plots, the x-axis indicates the 10 fractions obtained from LOPIT-DC, the y-axis indicates the total protein distribution along the 10 fractions for adult (pink) and old (green) fish. Shaded areas indicate 50% of the replicate distribution. P-values indicate the results of the Hotelling T2 test, ($N=4$ pools per age group). D) Volcano plot depicting protein detergent insolubility changes in the aging killifish brain. The x-axis indicates the difference in detergent insolubility score (see methods) expressed as old vs. adult. Higher values indicate increased detergent insolubility in the old brain. Y-axis indicates the $-\log_{10}$ of the MANOVA test between adult and old profiles ($N=4$ pools per age group). Significant changes are highlighted by dashed lines (MANOVA adjusted $P<0.2$ and absolute Δ Detergent insolubility score >2). E) Post-translationally modified peptides affected by aging. The y-axis (left) indicates the percentage of affected sites in each dataset when compared to the young samples ($P<0.05$, moderated Bayes T-test, $N=3-4$). F) Barplots showing relative abundances of ubiquitinated peptides from DNAJA1 and HSPA6 across age groups (purple bars). The corresponding protein abundances are displayed as reference (red bars), $N=3-4$. G) Volcano plot showing changes in estimated kinase activity (using the algorithm from (76)) based on phosphoproteomics data from old vs. young fish brains. The x-axis indicates changes in estimated kinase activity, the y-axis indicates FDR corrected $-\log_{10}(P\text{-value})$, Fisher's test). H) Density distribution for kinases involved in the regulation of immune response (GO:0050776, upper panel) and RNA processing (GO:0006396, lower panel) against all other kinases from panel H. x-axis indicates the \log_2 Kinase activity enrichment value. I) Heatmap showing alterations of proteins linked to neurodegenerative diseases. Significant alterations in each dataset ($P<0.05$) are marked by black dots. J) Barplots displaying significantly changing ($P<0.05$, moderated Bayes T-test) MAPT/Tau phosphorylated (green) and ubiquitinated (purple) peptide. The values represent relative abundances to the young age group, after correction for protein changes (see methods, Figure S4B). Asterisks indicate the P-value of the moderated Bayes T-test ($N=3-4$). K) (Left panel)

1283 Immunofluorescence stainings for phosphorylated (AT100) Tau in brain cryo-sections of young and old *N. furzeri*. The
 1284 stainings were normalized over the amount of NeuN in order to account for the different amounts of neuronal cells between
 1285 young and old (N=5) animals. Scale bars = 20µm. (Right panel) Boxplot representation of mean intensity for phosphorylated
 1286 Tau normalized over the amount of NeuN. P-value indicates the results of a two-sample Wilcoxon test. *P ≤ 0.05; **P ≤
 1287 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Related to Table S2,S3,S4.

1288
 1289




1290
 1291

1292 **Figure S6: Age-associated alterations of proteins linked to human neurodegenerative disorders.** A-B) Examples of
 1293 proteins changing their subcellular localization profile or detergent insolubility. The top panels indicate either subcellular
 1294 fractionation profiles (as in Figure 1D) or detergent insolubility profiles. For subcellular fractionation, in each of the plots, the
 1295 x-axis indicates the 10 fractions obtained from LOPIT-DC and the y-axis indicates the total protein distribution along the 10
 1296 fractions for adult (12 wph, pink) and old (39 wph, green) fish. Shaded areas indicate 50% of the (N=4 pools) replicate
 1297 distribution. P-values indicate the results of the Hotelling T2 test. For detergent insolubility profiles, the x-axis indicates the
 1298 different detergent insolubility fractions: S=soluble, F1:F3=fractions after solubilization with buffers of increasing detergent
 1299 strength (see methods, Figure S2A). The y-axis indicates log2 protein quantities relative to the soluble (S) fraction. The shaded
 1300 area indicates 50% of the distribution across N=4 pools per age group. In the bottom panels, the PCA plot represents
 1301 relocalization for each protein. The contour line represents the density distribution of the different organelles (calculated as
 1302 the median between 12 wph and 39 wph), and the position of the protein at 39 wph is highlighted with a cross. The organelles
 1303 represented are the ones that possess the higher absolute changes in the log2 ratios between Euclidean distances from the
 1304 protein in the two age groups. Only for panel A, the boxplot on the right side indicates the detergent insolubility score in the
 1305 two age groups. C) Pieplot showing conserved modified residues between *Nothobranchius furzeri* and humans that display

1306 changes in abundance with aging. Data refers to proteins involved in neurodegenerative diseases in humans. D) Local sequence
1307 alignments between *Nothobranchius furzeri* proteins (bottom sequence) and best human BLAST hit (upper sequence) for
1308 different proteins involved in neurodegenerative diseases. Modified residues are highlighted in purple (ubiquitylation) and
1309 green (phosphorylation). E) Barplots displaying significantly changing ($P < 0.05$, moderated Bayes T-test) of modified peptides
1310 for the proteins shown in panel D. Asterisks indicate the P-value of the moderated Bayes T-test ($N=3-4$). The values represent
1311 relative abundances to the young (5 wph) age group after correction for protein changes (see methods, Figure S4B). Related
1312 to Figure S5 and Table S4.

1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346



1347

1348

1349

1350

1351

1352

1353

1354

1355

1356

1357

1358


1359

1360

Figure S7: Alterations of ribosomal and respiratory chain proteins. A) Scheme of data integration strategy. For each dataset, a gene set enrichment analysis (GSEA) was performed using GO terms for cellular components. The normalized enrichment scores (NES) from each dataset were combined in a matrix and used as input for principal component analysis. B) Barplot showing transcript and protein abundances for oxidative phosphorylation protein. All the values were normalized to the 5 wph (young) age group (set to 1), N=3-4. C) Boxplot depicting the distribution of protein-transcript decoupling values (as defined in Figure 2A) for oxidative phosphorylation (light gray) proteins against the rest of the mitochondrial proteome (dark gray). Asterisks indicate the results of a two-sample Wilcoxon test. D-F) Examples of mitochondrial proteins that display changes in subcellular fractionation with aging. The x-axis indicates the 10 fractions obtained from LOPIT-DC, and the y-axis indicates the total protein distribution along the 10 fractions for adult (12 wph, pink) and old (39 wph, green) animals. Shaded areas indicate 50% of the replicate distribution from N=4 pools per group. P-values indicate the results of the Hotelling T2 test. G) Barplot showing transcript and protein abundances for cytoplasmic ribosomal protein. All the values were normalized to the 5 wph (young) age group (set to 1), N=3-4. H) Line plot showing the trajectories for transcriptome (blue) and proteome (red) for Mito. ribosome large sub. (P = 3.95E-17) and Mito. ribosome small sub. (P = 7.19E-13) at 5wph, 12wph, 20wph, and 39wph. Legend: Transcript (blue), Protein (red). I) Violin plot of median detergent insolubility score for Mito. ribosomes at 12wph (pink) and 39wph (green). Asterisks indicate statistical significance. J) Line plot of median effect size for RNA Polymerase II at 5wph, 12wph, 20wph, and 39wph. Legend: Transcript (blue), Protein (red). P = 1.54E-14. K) Violin plot of median detergent insolubility score for RNA Polymerase II at 12wph (pink) and 39wph (green). Asterisks indicate statistical significance.

1361 (red) of mitochondrial large and small ribosomal subunits. Each point summarizes the median distribution of the log₂ ratio of
1362 the quantities relative to the first (5 wph) age group, while the line bars indicate 50% of the distributions. P-values indicate the
1363 results of a MANOVA test run on the two multivariate distributions, N=3-4. I) Violin plot displaying detergent insolubility
1364 score for proteins of the mitochondrial ribosome (GO:0005761). Each dot represents the median insolubility score of each
1365 protein across N=4 pools per age group; asterisks indicate the results of a two-sample Wilcoxon test. J) Line plot showing the
1366 trajectories for transcriptome (blue) and proteome (red) for RNA Polymerase II enzyme. Each point summarizes the median
1367 distribution of the log₂ ratio of the quantities relative to the first (5 wph) age group, while the line bars indicate 50% of the
1368 distributions. P-values indicate the results of a MANOVA test run on the two multivariate distributions, N=3-4. K) Violin plot
1369 displaying detergent insolubility score for proteins of the RNA Polymerase II enzyme (GO:0016591). Each dot represents the
1370 median insolubility score of each protein across N=4 pools per age group; asterisks indicate the results of a two-sample
1371 Wilcoxon test. *P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Related to Figure 3.

1372



1373

1374

1375

1376

1377

1378

1379

1380

1381

1382


1383

1384

Figure S8: Effect of proteasome impairment on the killfish brain. A) Protein abundance changes induced by proteasome impairment for different components of the proteostasis network. B) (Right panel) Immunofluorescence stainings for lysosome (LAMP1) in brain cryo-sections of young (light blue) and old (green) *Nothobranchius furzeri*. Scale bars = 5µm. (Left panel) Barplot representation of lysosome morphology features in young (light blue) and old (green) samples. The y-axis represents the mean value of the different morphology features in each of the replicates (N=6). C) Effect of proteasome impairment on mitochondrial transcripts and proteins. For protein data, asterisks indicate the Q-value of the differential abundance testing performed with a two-sample T-test on the peptide abundances. For transcript data, asterisks indicate the Adjusted P-value of the differential abundance testing. N=10. D) Quantification of mitochondrial DNA (mt-DNA) from killfish brains during aging. Relative mtDNA copy number was calculated using real-time quantitative PCR with primers for 16S rRNA mitochondrial gene and Cdkn2a/b nuclear gene for normalization (N=5). Asterisks indicate the results of two-sample Wilcoxon

1385 tests. E) Violin plot showing the distribution of up and down-regulated proteins in response to proteasome impairment against
1386 their half-life as quantified in (16). Asterisks indicate the results of a two-samples Wilcoxon test. F) (Top left panel) Scatterplot
1387 comparing protein- (x-axis) and transcript-level (y-axis) fold changes in killifish after treatment with bortezomib. The color of
1388 each dot represents the decoupling score calculated as the difference between log₂ transformed fold changes measured at the
1389 protein and transcript levels. Grey dashed lines indicate the equal changes between transcript and protein and, therefore, a zero
1390 decoupling score. (Bottom left panel) Density distribution of decoupling scores for comparing bortezomib vs. DMSO. On the
1391 right part, highlighted in red, are protein “gain” events (increase in protein abundance compared to the transcript), while on
1392 the left, in blue, are protein “loss” events (decrease in protein abundance compared to the transcript). (Right panel) Multiple
1393 linear regression analysis of decoupling scores in response to proteasome impairment based on biophysical features of
1394 transcripts or proteins as predictors. The x-axis indicates the estimate of the regression coefficient for each feature, while the
1395 size of the dots and asterisks represent the -log₁₀ P-values of the F-test. *P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
1396 Related to Figure 3 and Table S5.

1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408



1409

1410 **Figure S9: Ribosome profiling in the killifish aging brain.** A) Tri-nucleotide plot showing characteristic triplet periodicity.
 1411 The x-axis represents the distance from the starting codon (in nucleotide) and the y-axis the number of reads. B) Scatterplot
 1412 showing the correlation between replicates for the Ribo-Seq experiment. On the different axis, the log₂(RPKM) values from
 1413 the different replicates are shown. C) Scatterplot showing the correlation between log₂ fold changes for ribosome occupancy

1414 (y-axis) and changes in the transcriptome (x-axis) for different aging steps. D) Boxplot displaying differential modes of
1415 regulation for different protein complexes. On the x-axis are displayed the different datasets: Transcriptome (green),
1416 Translation efficiency (purple), and Proteome (red). E) Immunoblot to detect RPS3 ubiquitylation in killifish cells treated with
1417 Anisomycin, which inhibits translation elongation and causes ribotoxic stress (99) for 24 hours. F) Immunoblot to detect RPS3
1418 ubiquitylation across age groups. Barplot shows the ratio between the total RPS3 and its ubiquitylated fraction during aging.
1419 Asterisks indicate the results of an ordinary one-way ANOVA test (N=4). G) Barplots displaying significantly changing
1420 ($P < 0.05$, moderated Bayes T-test) of ubiquitin-modified peptides for ribosomal proteins. Asterisks indicate the P-value of the
1421 moderated Bayes T-test (N=3-4). The values represent relative abundances to the young (5 wph) age group after correction for
1422 protein changes (see methods, Figure S4B). H) Barplot showing normalized protein abundance (relative to the first, 5 wph,
1423 age group set to 1) for factors associated with Ribosome-Quality-Control (RQC) pathways. The y-axis represents protein
1424 abundances relative to the first (5 wph) age groups. Asterisks indicate the Q-value of the differential abundance testing
1425 performed with a two-sample T-test on the peptide abundances, N=3,4 pools per group. I) 2-D density plot showing the relation
1426 between significant changes in pausing (Adjusted P-value < 0.05) displayed on the y-axis and changes in detergent insolubility
1427 metrics (x-axis). Each point in the distribution represents a significantly altered pausing site. Contour lines indicate the
1428 distribution of cytoplasmic ribosomes (red), Proteasome (black), and oxidative phosphorylation (white). J) Weblogo for
1429 disome pausing sites that display a strong increase in pausing (Pause score > 10). The y-axis displays the relative frequencies
1430 of the different residues, while the x-axis displays the different ribosome positions (E, P, A). K) Boxplot showing the
1431 distributions of pausing sites for cytoplasmic ribosomes (left panel) and respiratory chain complexes (right). Each dot
1432 represents a significantly altered (Adjusted P-value < 0.05) pausing site. The Y axis represents the \log_2 fold changes in pausing
1433 between 39 wph and 5 wph. * $P \leq 0.05$; ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$. Related to Figure 4 and Table S6.
1434

1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463